The University of Nebraska at Omaha has announced it has terminated the research of a researcher who was involved in a massive outbreak of skin cancer.
The University of Omaha’s Center for Human Genome Biology (CHGB) has conducted research at the University of Maryland in College Park and was contracted to conduct clinical trials for the university.CHGB conducted a phase II trial of an investigational new drug, BSM.
BSM was developed by a small team of scientists and has the potential to be an alternative to current cancer therapies.
The NIH has also said that the University has an ethical obligation to follow the guidelines in place for NIH research.
The University says it will not re-enter phase II clinical trials.
University of Maryland professor of pathology Andrew Linnemann is the lead investigator on the study.
Linneman says the University followed a very strict process.
“We are not at the point of doing anything that’s unethical, but there is a lot of ethical questions around how we do things here,” he said.
“And, I guess, the only way I can answer those questions is to go through the NIH’s ethical approval process.
And that’s the process that we’re following right now.
We are not trying to say that this is right or wrong.
We’re trying to follow what is the NIH process.”
The university says Linneman is a registered nurse and is a member of the Nebraska Medical Board.
He says he is not connected to any clinical trials at the time.
“It is not appropriate for me to comment on this particular case,” Linnmann said.
“I can say that I have received the highest professional ethics approval in the world from the NIH.”
The University says there are many ways that researchers can participate in the NIH-funded studies.
However, there are no restrictions on research on human subjects.
“I would like to acknowledge and thank the NIH for their support in our efforts to protect the rights of our patients,” Linnean said.
The university has said it is looking into ways to return to human subjects research.